45
Participants
Start Date
December 12, 2019
Primary Completion Date
December 20, 2023
Study Completion Date
December 20, 2023
Modakafusp Alfa
Modakafusp alfa intravenous infusion.
Pembrolizumab
Pembrolizumab intravenous infusion.
Ballarat Regional Integrated Cancer Center, Ballarat
The Queen Elizabeth Hospital, Woodville South
University of Pittsburgh Medical Center, Pittsburgh
West Virginia University Health Sciences Campus, Morgantown
Orlando Health Cancer Institute, Orlando
Sylvester Comprehensive Cancer Center, Miami
Sarah Cannon Research Institute, Nashville
Cleveland Clinic Main Campus, Cleveland
Avera Cancer Institute, Sioux Falls
Texas Oncology - Baylor Charles A. Sammons Cancer Center, Dallas
University of Colorado Health Memorial Hospital Central, Colorado Springs
Intermountain Medical Center, Murray
The Angeles Clinic and Research Institute - West Los Angeles Office, Los Angeles
City of Hope Comprehensive Cancer Center - Duarte, Duarte
University of California San Diego Moores Cancer Center, La Jolla
Norris Cotton Cancer Center Lebanon, Lebanon
Morristown Medical Center, Morristown
Lead Sponsor
Takeda
INDUSTRY